Emmessar Biotech Financial Statements
Emmessar Biotech financial statements. In FYNone, Emmessar Biotech (EMMESSA) reported revenue ₹2 Cr, net profit ₹0 Cr and EPS ₹0.70. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Read EMMESSA dividend history for the complete payout history and dividend yield track record.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
EMMESSA Revenue, Net Profit & EBITDA — Year-on-Year Growth
EMMESSA YoY (March 2026 vs Period). Analyse EMMESSA shareholder distribution to track promoter, FII and institutional holdings.
EMMESSA Income Statement — Revenue, EBITDA & Net Profit
Emmessar Biotech revenue ₹2 Cr, EBITDA ₹1 Cr, net profit ₹0 Cr, EPS ₹0.70 (None). For live price, earnings ratios and company overview, see EMMESSA screener.
| Particulars | None | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 2 | 3 | 3 | 3 | 2 | 9 | 5 | 2 | 3 | 4 | 2 | 2 |
| Expenses | 2 | 2 | 2 | 2 | 2 | 1 | 6 | 4 | 1 | 2 | 2 | 2 | 2 |
| EBITDA | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 0 | 0 |
| Operating Profit Margin % | -446.00% | -365.00% | -156.00% | -195.00% | -68.00% | -245.00% | 12.00% | -12.00% | -102.00% | -32.00% | 9.00% | 1.00% | -7.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 1 | 1 | -1 | 0 |
| Tax | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | -1 | 0 |
| Earnings Per Share (₹) | 0.70 | 0.87 | 0.63 | 1.50 | 0.99 | 0.94 | 2.90 | 1.51 | 1.05 | 1.83 | 2.36 | -0.93 | -0.24 |
EMMESSA Balance Sheet — Assets, Liabilities & Shareholders' Equity
EMMESSA total assets ₹10 Cr, total equity ₹8 Cr, total liabilities ₹ Cr (2026).
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| Total Assets | 10 | 9 | 9 | 8 | 7 | 8 | 6 | 5 | 4 | 3 | 2 | 2 |
| Current Assets | 8 | 7 | 7 | 6 | 5 | 5 | 3 | 2 | 1 | 1 | 1 | 1 |
| Fixed Assets | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 8 | 7 | 7 | 6 | 5 | 6 | 4 | 3 | 2 | 2 | 2 | 1 |
| LIABILITIES | ||||||||||||
| Total Liabilities | ||||||||||||
| Current Liabilities | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Non-Current Liabilities | ||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||
| Total Equity | 8 | 8 | 7 | 7 | 6 | 6 | 4 | 4 | 3 | 2 | 1 | 1 |
| Share Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves & Surplus | 3 | 3 | 2 | 2 | 1 | 1 | -1 | -2 | -2 | -3 | -4 | -4 |
EMMESSA Cash Flow Statement — Operating, Investing & Financing
Emmessar Biotech operating cash flow ₹0 Cr, investing ₹0 Cr, financing ₹0 Cr, net cash flow ₹0 Cr (2026).
| Particulars | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 0 | 0 | 1 | 0 | 2 | 1 | 1 | 0 | 1 | 1 | 0 | 0 |
| Investing Activities | 0 | 0 | -1 | -1 | -3 | 0 | -1 | 0 | -1 | -1 | -1 | 0 |
| Financing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |